BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35553368)

  • 1. Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.
    Williams JF; Zhao M; Najdawi F; Ahmadi S; Hornick JL; Wong KS; Barletta JA
    Endocr Pathol; 2022 Sep; 33(3):371-377. PubMed ID: 35553368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.
    Lubin DJ; Behrman DB; Goyal S; Magliocca K; Shi Q; Chen AY; Viswanathan K
    Mod Pathol; 2023 Sep; 36(9):100235. PubMed ID: 37270155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation.
    Viswanathan K; Behrman DB; Lubin DJ
    Cancer Cytopathol; 2024 Apr; 132(4):224-232. PubMed ID: 38062948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.
    Vissio E; Maletta F; Fissore J; Osella Abate S; Retta F; Brizzi MP; Piovesan A; Rossetto Giaccherino R; Volante M; Papotti M
    Endocr Pathol; 2022 Sep; 33(3):359-370. PubMed ID: 35583706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
    J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of Digital Image Analysis for Ki67 Quantification in the Grading of Medullary Thyroid Carcinoma: A Pilot Study with 85 Cases.
    Behrman DB; Lubin DJ; Magliocca K; Shi Q; Viswanathan K
    Head Neck Pathol; 2023 Sep; 17(3):638-646. PubMed ID: 37294412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International medullary thyroid carcinoma grading system: an Indian tertiary care centre experience.
    Rai V; Saha A; Mehta S; Shah RA; Trivedi P; Samanta ST; Rathod P; Manimaran P
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1571-1579. PubMed ID: 38010402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.
    Fuchs TL; Nassour AJ; Glover A; Sywak MS; Sidhu SB; Delbridge LW; Clifton-Bligh RJ; Gild ML; Tsang V; Robinson BG; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Am J Surg Pathol; 2020 Oct; 44(10):1419-1428. PubMed ID: 32452872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
    Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
    Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas.
    Najdawi F; Ahmadi S; Capelletti M; Dong F; Chau NG; Barletta JA
    Histopathology; 2021 Sep; 79(3):427-436. PubMed ID: 33763905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma.
    Nigam A; Xu B; Spanheimer PM; Ganly I; Tuttle RM; Wong RJ; Shaha AR; Ghossein RA; Untch BR
    Thyroid; 2022 Oct; 32(10):1193-1200. PubMed ID: 35950622
    [No Abstract]   [Full Text] [Related]  

  • 12. Medullary Thyroid Carcinomas Classified According to the International Medullary Carcinoma Grading System and a Surveillance, Epidemiology, and End Results-Based Metastatic Risk Score: A Correlation With Genetic Profile and Angioinvasion.
    Torricelli F; Santandrea G; Botti C; Ragazzi M; Vezzani S; Frasoldati A; Ghidini A; Giordano D; Zanetti E; Rossi T; Nicoli D; Ciarrocchi A; Piana S
    Mod Pathol; 2023 Sep; 36(9):100244. PubMed ID: 37307881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma.
    Aksoy YA; Xu B; Viswanathan K; Ahadi MS; Al Ghuzlan A; Alzumaili B; Bani MA; Barletta JA; Chau N; Chou A; Clarkson A; Clifton-Bligh RJ; De Leo A; Dogan S; Ganly I; Ghossein R; Gild ML; Glover AR; Hadoux J; Lamartina L; Lubin DJ; Magliocca K; Najdawi F; Nigam A; Papachristos A; Repaci A; Robinson BG; Sheen A; Shi Q; Sidhu SB; Sioson L; Solaroli E; Sywak MS; Tallini G; Tsang V; Turchini J; Untch BR; Gill AJ; Fuchs TL
    Histopathology; 2024 May; 84(6):947-959. PubMed ID: 38253940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grading system for medullary thyroid carcinoma; an institutional experience.
    Podany P; Meiklejohn K; Garritano J; Holt EH; Barbieri A; Prasad M; Gilani SM
    Ann Diagn Pathol; 2023 Jun; 64():152112. PubMed ID: 36736129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necrosis is an independent predictor of disease-free and overall survival in pancreatic well-differentiated neuroendocrine tumours (NETs): a proposal to include it in grading systems.
    Fuchs TL; Chou A; Ahadi M; Sheen A; Sioson L; Mittal A; Samra J; Gill AJ
    Pathology; 2022 Dec; 54(7):855-862. PubMed ID: 35934531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: A study from North India.
    Marwah N; Batra A; Marwah S; Gupta V; Shakya S; Sen R
    J Cancer Res Ther; 2018; 14(3):537-542. PubMed ID: 29893312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance and interrelations of PD-L1 expression, Ki-67 index, and molecular alterations in sporadic medullary thyroid carcinoma from a Chinese population.
    Bai Y; Guo T; Niu D; Zhu Y; Ren W; Yao Q; Huang X; Feng Q; Wang T; Ma X; Ji X
    Virchows Arch; 2022 Dec; 481(6):903-911. PubMed ID: 35920918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
    Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
    Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database.
    Le MK; Kawai M; Odate T; Vuong HG; Oishi N; Kondo T
    Endocr Pathol; 2022 Sep; 33(3):348-358. PubMed ID: 35852678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
    Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
    Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.